Antonina Sidoti Selected Research

trimethylamine

11/2021	Adaptive Modelling of Mutated FMO3 Enzyme Could Unveil Unexplored Scenarios Linking Variant Haplotypes to TMAU Phenotypes.
4/2021	Antiretroviral treatment leading to secondary trimethylaminuria: Genetic associations and successful management with riboflavin.
1/2021	Gut-Brain Axis Cross-Talk and Limbic Disorders as Biological Basis of Secondary TMAU.
12/2014	Regulation of flavin-containing mono-oxygenase (Fmo3) gene expression by steroids in mice and humans.
10/2014	Fish odor syndrome (trimethylaminuria) supporting the possible FMO3 down expression in childhood: a case report.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Antonina Sidoti Research Topics

Disease

6	Trimethylaminuria 11/2021 - 02/2013
5	Retinitis Pigmentosa (Pigmentary Retinopathy) 03/2021 - 11/2018
3	Retinal Degeneration 01/2021 - 11/2018
2	Inflammation (Inflammations) 01/2022 - 01/2021
2	Atrophy 03/2021 - 09/2008
2	Retinal Dystrophies 12/2020 - 04/2020
2	Bipolar Disorder (Manic Depressive Psychosis) 01/2016 - 08/2015
2	Schizophrenia (Dementia Praecox) 08/2015 - 02/2012
1	Inborn Genetic Diseases (Disease, Hereditary) 11/2021
1	Night Blindness (Nyctalopia) 03/2021
1	Mental Disorders (Mental Disorder) 01/2021
1	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2021
1	Neuroinflammatory Diseases 12/2020
1	Starvation 04/2020
1	Gilbert Disease 01/2015
1	Hyperbilirubinemia 01/2015
1	Major Depressive Disorder (Major Depressive Disorders) 07/2013
1	Body Odor 02/2013
1	Breast Neoplasms (Breast Cancer) 01/2012
1	Neoplasms (Cancer) 01/2012
1	Multiple Sclerosis 01/2011
1	Genetic Predisposition to Disease (Genetic Predisposition) 01/2011
1	Muscular Diseases (Myopathy) 09/2008
1	Muscular Dystrophies (Muscular Dystrophy) 09/2008
1	Polyneuropathies (Polyneuropathy) 09/2008
1	Duchenne Muscular Dystrophy (Muscular Dystrophy, Becker) 09/2008

Drug/Important Bio-Agent (IBA)

6	Retinaldehyde (Retinal)IBA 03/2021 - 01/2019
5	trimethylamineIBA 11/2021 - 10/2014
4	dimethylaniline monooxygenase (N-oxide forming) (flavin-containing monooxygenase)IBA 04/2021 - 02/2013
3	RNA (Ribonucleic Acid)IBA 05/2020 - 01/2019
2	A2-E (N-retinylidene-N-retinylethanolamine)IBA 01/2021 - 11/2020
2	Reactive Oxygen Species (Oxygen Radicals)IBA 12/2020 - 04/2020
2	trimethyloxamine (trimethylamine N-oxide)IBA 10/2014 - 02/2013
1	Thrombin FDA Link 01/2022
1	Proteinase-Activated ReceptorsIBA 01/2022
1	Riboflavin (Vitamin B2)FDA LinkGeneric 04/2021
1	Serotonin (5 Hydroxytryptamine)IBA 01/2021
1	CytokinesIBA 01/2021
1	Biomarkers (Surrogate Marker)IBA 01/2021
1	Ion Channels (Ion Channel)IBA 12/2020
1	Mitochondrial DNA (mtDNA)IBA 11/2020
1	Oxidants (Oxidizing Agents)IBA 05/2020
1	Melanins (Melanin)IBA 04/2020
1	Amino Acids FDA Link 04/2020
1	CarbohydratesIBA 04/2020
1	oxidized low density lipoproteinIBA 11/2018
1	Biological ProductsIBA 01/2016
1	HLA-DR alpha-ChainsIBA 08/2015
1	HLA-C Antigens (HLA-C)IBA 08/2015
1	Complement System Proteins (Complement)IBA 08/2015
1	BilirubinIBA 01/2015
1	UGT1A1 enzymeIBA 01/2015
1	OxidesIBA 12/2014
1	EnzymesIBA 10/2014
1	Carrier Proteins (Binding Protein)IBA 07/2013
1	ElementsIBA 07/2013
1	Mitogen-Activated Protein Kinase 1 (p42 MAP Kinase)IBA 07/2013
1	Cyclic AMP (AMP, Cyclic)IBA 07/2013
1	Antidepressive Agents (Antidepressants)IBA 07/2013
1	Antipsychotic Agents (Antipsychotics)IBA 02/2012
1	Cyclin D1IBA 01/2012
1	CC ChemokinesIBA 01/2011
1	Messenger RNA (mRNA)IBA 09/2008
1	Sarcoglycans (beta Sarcoglycan)IBA 09/2008
1	Proteins (Proteins, Gene)FDA Link 09/2008
1	AgrinIBA 09/2008
1	IntegrinsIBA 09/2008

Therapy/Procedure

1	Therapeutics 01/2021